{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:07:53Z","timestamp":1764936473215},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T00:00:00Z","timestamp":1215475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Despite advances in surveillance strategies and antivirals, cytomegalovirus (CMV) infection continues to pose problems to patients receiving hematopoietic stem cell transplants (HSCTs). The bone marrow transplant (BMT) unit at the Singapore General Hospital embraced the preemptive strategy in late 2003. Although several studies have demonstrated its usefulness, we conducted this review to document CMV\u2010related events at our institution. Forty\u2010six patients underwent CMV surveillance using the CMV pp65 antigenemia (CMV Ag) assay from January 2004 to December 2005. Twenty\u2010seven patients had CMV infection, and 19 remained antigenemia\u2010negative. No differences were found between the 2 groups for the following potential risk factors for CMV infection: age, total number of co\u2010morbidities, duration of neutropenia after conditioning, baseline creatinine, type of conditioning regimen (conventional vs. reduced intensity), type of transplant (matched sibling vs. others), recipient CMV status, donor CMV status, and use of total body irradiation. Two patients received alemtuzumab; both developed CMV Ag. Twelve episodes of CMV infection occurred after the 100th post\u2010HSCT day. Two patients developed CMV disease. One of them could be considered a failure of the preemptive strategy, as she had CMV gastritis diagnosed on the same day that she became pp65\u2010positive. The other developed CMV disease despite prompt institution of ganciclovir, although she had multiple post\u2010HSCT complications requiring enhanced immunosuppression, as well as relapsed disease. One\u2010year disease\u2010free survival was 55.5% in those with CMV infection and 52.3% in those without infection. Survival was not affected by CMV infection.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2008.00325.x","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T11:08:57Z","timestamp":1215515337000},"page":"325-332","source":"Crossref","is-referenced-by-count":12,"title":["Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real\u2010world review"],"prefix":"10.1111","volume":"10","author":[{"given":"B.H.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.L.","family":"Chlebicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.","family":"Hong Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.Y.R.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.P.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.T.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,21]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"543","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"9","author":"Boeckh M","year":"2003","journal-title":"current status, known challenges, and future strategies"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2004.02.022"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104113241501"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104113241509"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.7.2815.2815"},{"key":"e_1_2_6_7_2","first-page":"583","article-title":"Use of a semi\u2010quantitative PCR for cytomegalovirus DNA as a basis for pre\u2010emptive antiviral therapy in allogeneic bone marrow transplant patients","volume":"17","author":"Ljungman P","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199701000-00006"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V93.5.1781","article-title":"Successful modification of a pp65 antigenemia\u2010based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients","volume":"93","author":"Boeckh M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2240"},{"key":"e_1_2_6_11_2","first-page":"304","article-title":"Cytomegalovirus infections following unrelated cord blood transplantation for adult patients","volume":"121","author":"Tomonari A","year":"2003","journal-title":"a single institute experience in Japan"},{"key":"e_1_2_6_12_2","first-page":"105","article-title":"Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients","volume":"69","author":"Matsunaga T","year":"1999","journal-title":"Int J Hematol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.12.4356-4360.2000"},{"key":"e_1_2_6_14_2","first-page":"2122","article-title":"Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay","volume":"38","author":"Caliendo AM","year":"2000","journal-title":"clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.11.3938-3941.2001"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.5.2040-2046.2003"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704797"},{"key":"e_1_2_6_18_2","first-page":"753","article-title":"Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir","volume":"13","author":"Bacigalupo A","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia\u2010guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplant \u2013 a randomised double\u2010blind study","volume":"88","author":"Boeckh M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.026484"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.4.1430-1433.2000"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/339329"},{"key":"e_1_2_6_23_2","first-page":"635","volume-title":"Thomas' Hematopoietic Stem Cell Transplantation","author":"Sullivan K.","year":"2004"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.5.901"},{"key":"e_1_2_6_25_2","first-page":"867","article-title":"Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation","volume":"97","author":"Garrett Nichols W","year":"2001","journal-title":"risk factors, correlation with DNA load, and outcomes"},{"key":"e_1_2_6_26_2","first-page":"801","article-title":"Cytomegalovirus antigenemia and outcome of patients treated with pre\u2010emptive ganciclovir","volume":"32","author":"Yanada M","year":"2003","journal-title":"retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38398222871.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.140123497"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/514572"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1128\/jcm.31.11.2851-2856.1993","article-title":"Comparisons of quantitative cytomegalovirus antigenemia assay and culture methods and correlation with clinical disease","volume":"31","author":"Landry ML","year":"1993","journal-title":"J Clin Microbiol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/378413"},{"key":"e_1_2_6_32_2","first-page":"449","volume-title":"Thomas' Hematopoietic Stem Cell Transplantation","author":"Blume KG","year":"2004"},{"key":"e_1_2_6_33_2","first-page":"273","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)\u2010seronegative recipients of stem cell transplant from seropositive donors","volume":"185","author":"Garrett Nichols W","year":"2002","journal-title":"evidence for indirect effects of primary CMV infection"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2008.00325.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2008.00325.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:29:15Z","timestamp":1696868955000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2008.00325.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,21]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1399-3062.2008.00325.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2008.00325.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,21]]}}}